CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer
Authors
Powles, T.Mendez-Vidal, M. J.
Rodriguez-Vida, A.
Perez-Valderrama, B.
Esteban, E.
Thistlethwaite, Fiona C
Patel, P. M.
Herranz, U. A.
Srinivasan, G.
Hamid, A.
Larkin, J.
Ralph, C.
Symeonides, S. N.
Puente, J.
Hartmaier, R.
Markovets, A.
Prendergast, A.
Mousa, K.
Suarez, C.
Affiliation
Barts ECMC, Barts Cancer Institute, Queen Mary University of London, LondonIssue Date
2022
Metadata
Show full item recordCitation
Powles T, Mendez-Vidal MJ, Rodriguez-Vida A, Perez-Valderrama B, Esteban E, Thistlethwaite F, et al. CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer. Journal of Clinical Oncology. 2022 Jun;40(17). PubMed PMID: WOS:000891791500023.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.17_suppl.LBA4503Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.17_suppl.LBA4503Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.17_suppl.LBA4503